Core Insights - Tourmaline Bio, Inc. reported its financial results for Q1 2025, highlighting its focus on developing transformative medicines for immune and inflammatory diseases [1][8] - The company is preparing for the topline data presentation from its Phase 2 TRANQUILITY trial of pacibekitug, which targets IL-6-driven cardiovascular inflammation [2][5] Financial Performance - As of March 31, 2025, Tourmaline had cash, cash equivalents, and investments totaling $275.3 million, down from $294.9 million at the end of 2024, providing a cash runway into the second half of 2027 [8][16] - Research and development expenses for Q1 2025 were $20.3 million, an increase from $11.4 million in Q1 2024, primarily due to higher clinical trial costs [13][15] - The net loss for Q1 2025 was $23.0 million, resulting in a basic and diluted net loss per share of $0.89, compared to a net loss of $13.3 million and a loss per share of $0.55 in Q1 2024 [13][15] Clinical Development Highlights - The Phase 2 TRANQUILITY trial has over-enrolled with 143 participants, exceeding the initial target of 120, and is on track for topline data readout in Q2 2025 [6][5] - Tourmaline plans to provide further details on the clinical development plan for pacibekitug in cardiovascular inflammation alongside the TRANQUILITY topline data [5][6] - The company is also advancing its development of pacibekitug for additional indications, including abdominal aortic aneurysm (AAA) [6][11] Research and Publications - Tourmaline's research team has contributed to publications regarding the role of IL-6 in thyroid eye disease and cardiovascular inflammation, indicating ongoing engagement with the scientific community [7][6] - The company presented findings at major medical conferences, enhancing its visibility and collaboration with cardiovascular disease experts [2][6]